Skip to main content
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2020 Mar 4;13:1907–1908. doi: 10.2147/OTT.S250149

SMAGP a Novel Biomarker of Cervical Cancer Development and Progression [Erratum]

PMCID: PMC7063802  PMID: 32184625

Jia Y, Li H, Liu G, Song F. OncoTargets Ther. 2018;11:6925–6935.

On page 6933, Figure 4B artwork is incorrect. Figure 4B artwork was mistakenly interchanged by the Editorial staff during the publication process. The correct Figure 4 is as follows:

Figure 4.

Figure 4

SMAGP down-regulation inhibited the migration and invasion ability of cervical cancer cells.

Notes: (A, B) SMAGP was knocked down with siRNA(siNCand si581) and lentivirus (shNC, shSMAGP). Knockdown of SMAGP inhibited CaSki cell migration and invasion. (C) Knockdown of SMAGP inhibits CaSki metastasis in nude mice. CaSki cells stably expressing shSMAGP were injected into nude mice twice per week. At 28 days after injection, the tumor mass and related tissues were removed. In the NCgroup, many tumors were found around the intestine; however, tumors only developed at the injection site in the experimental group. Ascites extracted from the NC group exhibited green fluorescence. **P,0.01, ***P,0.001. Magnification 100×.

Abbreviation: NC, normal cells.


Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES